RECEIVED **CENTRAL FAX CENTER**

OCT 0 4 2005

FAX TRANSMISSION

DATE:

October 4, 2005

PTO IDENTIFIER:

Application Number 10/645,312-Conf. #7622

Tacyoung Yoon et al.

MESSAGE TO:

US Patent and Trademark Office

FAX NUMBER:

(571) 273-8300

FROM:

EDWARDS & ANGELL, LLP

John B. Alexander, Ph.D.

PHONE:

(617) 439-4444

Attorney Dkt, #:

58288(72021)

PAGES (Including Cover Sheet): 30

CONTENTS:

Amendment Transmittal (1 page); Amendment (28 pags).

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 439-4444 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

EDWARDS & ANGELL, LLP

P.O. Box 55874, Boston, Massachusotts 02205 Telephone: (617) 439-4444 Facsimile: (617) 439-4170

RECEIVED CENTRAL FAX CENTER

OCT 0 4 2005

AMENDMENT TRANSMITTAL LETTER						Docket No. 58288(72021)	
Application No. 10/645,312-Conf. #7622		Filing Date August 20, 2003		Examiner Z. C. Tucker		Art Unit 1624	
Applicant(s): Taeyoung Yoon et al.							
Invention: 5-SUBSTITUTED-2-ARYLPYRAZINES							
TO THE COMMISSIONER FOR PATENTS Transmitted horowith is an amendment in the above-identified application.							
The fee has been calculated and is transmitted as shown below.							
	Claims	CLAIM Highest	S AS AMEN	DED	~~ ~~~~~		
	Remaining After Amendment	Number Previously Paid	Numbor Extra Claims Present	Rate			
Total Claims		- 20 =		×		·-	
Independent Claims		- 3 =	ļ	x			
Multiple Dependent Claims (check if applicable)							
Other fee (please specify):							
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT: 0,00							
X Large Entity Small Entity							
x No additional fee is required for this amendment.							
Please charge Deposit Account No in the amount of \$ A duplicate copy of this sheet is enclosed.							
A check in the amount of \$ to cover the filing fee is enclosed.							
Payment by credit card. Form PTO-2038 is altached.							
The Director is hereby authorized to charge and credit Deposit Account No. 04-1105 as described below. A duplicate copy of this sheet is enclosed.							
Tx Credit any overpayment							
Charge arryladditional fling or and lication processing fees required under 37 CFR 1.16 and 1.17.							
John B. Mexander, Ph.D. Allorney/Reg. No.: 48,399							
EDWARDS & ANGELL, LLP							
P.O. Box 55874 Boston, Massachusetts 02205							
(617) 439-4444							
			·				
1 horoby certify that this correspondence is being facsimile transmitted to the Palant and Trademark Office, facsimile no. (571) 273-0300 , on the date shown below.							
Dated. October 4, 2005 Signature: Bruncup (Bonnie S. Crespi)							

OCT 0 4 2005

I hereby certify that this correspondence is being facsimite transmitted to the Putont and Tradomark Office, facsimite no. 571-273-8300, on the date shown below.

Signature:

Dated: October 4, 2005

(Bonnia S. Crospi)

Docket No.: 58288(72021) (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Taeyoung Yoon et al.

Application No.: 10/645,312

Confirmation No.: 7622

Filed: August 20, 2003

Art Unit: 1624

For: 5-SUBSTITUTED-2-ARYLPYRAZINES

Examiner: Z. C. Tucker

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

Applicants are in receipt of the Office Action dated July 6, 2005 and request reconsideration of the above-identified application in view of the following amendments and remarks. Please amend the above-identified application as follows:

Amendments to the Abstract begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 25 of this paper.